Bioversys

Focus area/active in: Therapeutics

Company/Organisation type: SME

About:
BioVersys AG is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance and targeted microbiome modulation. BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections. Our most advanced R&D programs are in preclinical development for nosocomial infections, and Tuberculosis in collaboration with GSK. In 2020 BioVersys plans to launch its first Phase I clinical trials.

Website: www.bioversys.com